Celldex (CLDX) has shared an update.
Celldex Therapeutics, Inc. stockholders, at their 2024 Annual Meeting, endorsed a key amendment expanding the stock pool by 3.2 million shares for their 2021 Omnibus Equity Incentive Plan and raised the award limit for non-employee directors. Additionally, they elected a slate of directors, ratified PricewaterhouseCoopers LLP as their independent auditor, and on an advisory basis, approved executive compensation. These decisions are set to influence the company’s governance and strategic incentive mechanisms moving forward.
Find detailed analytics on CLDX stock on TipRanks’ Stock Analysis page.
